• The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

  • Apr 24 2025
  • Length: 19 mins
  • Podcast

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Listen for free

View show details

  • Summary

  • In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including:

    • Rationale for targeting B7-H3
    • Overview of the structure of antibody-drug conjugates (ADCs)
    • Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLC
    • Data from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLC
    • An overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLC
    • Early phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093

    Program faculty:

    Lauren Byers, MD
    Professor and Thoracic Section Chief
    Department of Thoracic/Head and Neck Medical Oncology
    MD Anderson Cancer Center
    Houston, Texas

    Christine L. Hann, MD, PhD
    Associate Professor of Oncology
    Director, Small Cell Lung Cancer Therapeutics
    Johns Hopkins University School of Medicine
    Baltimore, Maryland
    Show more Show less
Show more Show less
adbl_web_global_use_to_activate_webcro768_stickypopup

What listeners say about The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available